Compare Regeneron Pharmaceuticals Inc (REGN) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Starbucks Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B), while Starbucks Corp trades at $93.22 (market cap $106.26B). The key difference: Starbucks Corp is the larger of the two by market cap, and Starbucks Corp pays the higher dividend (2.7%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Starbucks Corp for 190 Days on average.
| REGN | SBUX | |
|---|---|---|
Market Cap | $76.14B | $106.26B |
Volume | 500,239 | 30,248,434 |
Sector | Health | Consumer Cyclical |
52-Week High | $852.03 | $108.55 |
52-Week Low | $557.73 | $78.46 |
Typical Hold Time | 107 Days | 190 Days |
Enterprise Value | $70.85B | $125.08B |
Dividend Yield | 0.51% | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Starbucks (SBUX) trades at $93.58, down 2.63% amid bearish technical signals and recent store closure announcements. The company shows mixed fundamentals with a high P/E ratio of 54.09 but strong recent earnings beats. Revenue growth remains modest at $37.18B for 2025, while net income declined to $1.86B. Analyst consensus remains positive with a $115.50 price target despite ongoing restructuring challenges and geopolitical tensions in China operations.
The stock faces near-term pressure from operational restructuring but maintains long-term growth potential through international expansion and brand strength. Key risks include labor relations, Chinese market exposure, and execution of store optimization strategy. With 47% analyst buy ratings and solid dividend payments, SBUX offers value for patient investors despite current headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
